9 enrolling by invitation. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Enrolling by invitation 9 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| Alzheimer's Disease Research Center (ADRC) PET Component Study 18F-MK6240, 18F-Florbetaben (FBB) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Patrick Lao | 120 | 2026-08-06 | 2026-08-11 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-08-12 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-08-13 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis ML-007C-MA - Psychosis Associated With Alzheimer's Disease | Phase 2 | Enrolling by invitation | MapLight Therapeutics | 210 | 2026-03-25 | 2026-08-07 |
| Tau PET Outcomes With Anti-amyloid Immunotherapies 18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild | Phase 2 | Enrolling by invitation | Mayo Clinic | 135 | 2025-11-04 | 2026-10-30 |
| A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI Ginkgo Biloba Extract 761 - Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Hadassah Medical Organization | 50 | 2024-08-20 | 2025-12-17 |
| Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias C-11 ER-176, Blood Test - Lewy Body Dementia (LBD), Alzheimer Dementia (AD) | Phase 2 | Enrolling by invitation | Val Lowe | 125 | 2021-03-30 | 2026-05-22 |
| Neuroimaging Study Tau PET scan - Cognitive Impairment | Phase 2 | Enrolling by invitation | Mayo Clinic | 240 | 2018-11-26 | 2026-06-12 |
Alzheimer Disease (7) · Cognitive Dysfunction (4) · Dementia (4) · Frontotemporal Dementia (2) · Supranuclear Palsy, Progressive (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Delusions (1) · Hallucinations (1) · Lewy Body Disease (1) · Lymphoma, Follicular (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1)
Brain Diseases (8) · Central Nervous System Diseases (8) · Mental Disorders (8) · Nervous System Diseases (8) · Neurocognitive Disorders (8) · Neurodegenerative Diseases (8) · Dementia (5) · Cognition Disorders (4) · Pathological Conditions, Signs and Symptoms (4) · Basal Ganglia Diseases (3) · Frontotemporal Lobar Degeneration (3) · Movement Disorders (3) · Neurologic Manifestations (3) · Signs and Symptoms (3)
AADvac1 (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Ginkgo biloba extract (1) · Hematologic Tests (1) · LM11A-31 (1) · donanemab (1)
Adam Boxer (2) · Mayo Clinic (2) · Hadassah Medical Organization (1) · MapLight Therapeutics (1) · Patrick Lao (1) · Paul S. Aisen (1) · Val Lowe (1)
United States (8) · Bulgaria (1) · France (1) · Israel (1)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (2) · Irene Litvan, MD (2) · Julio Rojas-Martinez, MD, PhD (2) · Keith Johnson, MD (1) · Neill R Graff-Radford, MD (1) · Patrick J Lao, PhD (1) · Petrice Cogswell, M.D., Ph.D. (1) · Val Lowe, MD (1)
R01AG085029 (2), 2025 (1), P30AG066462 (1), P50AG016574 (1), R01AG078457 (1)